Abstract:Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and among the leading causes of cancer-related deaths worldwide.[1] [2] While early-stage HCC is amenable to curative therapy, intermediate- and late-stages require a team of hepatologists, surgeons, oncologists, and interventional radiologists to optimize treatment. Several staging systems have been proposed in the management of HCC, the most prominent being the Barcelona Clinic Liver Cancer (BCLC) Staging System which is endorsed by leading organizations in Europe and North America.[3] According to the BCLC System, HCC stage is assessed using measures of tumor burden, performance status, and liver function. Tumor burden incorporates the size, location, and number of lesions as well as portal invasion or extrahepatic spread. Performance status is determined using the Eastern Cooperative Oncology Group (ECOG) criteria.[4] Finally, liver function is classified as "preserved" or "end-stage." Measures of liver function have traditionally relied on Child–Pugh (CP) scores which stratify patients into three classes of liver function based on serum bilirubin, albumin, coagulation, and the presence or absence of ascites and hepatic encephalopathy.[5] The Model for End-Stage Liver Disease (MELD) scoring system, originally developed to predict outcomes of patients undergoing transjugular intrahepatic portosystemic shunt, overcomes some limitations of the CP system, namely, the subjectivity in rating ascites or encephalopathy which could inappropriately be used to benefit a patient's position on transplant lists.[6] New BCLC recommendations suggest incorporating α fetoprotein and albumin–bilirubin scores to accurately assess liver function in addition to these traditional measures. Tumor burden, performance status, and liver function are used in conjunction to stratify HCC into very early stage (0), early stage (A), intermediate stage (B), advanced stage (C), and terminal stage (D) ([Table 1]). Tumor burden Performance status Liver function Very early stage (0) Single ≤ 2 cm 0 Preserved Early stage (A) Single, or ≤ 3 nodules each ≤ 3 cm 0 Preserved Intermediate stage (B) Multinodular 0 Preserved Transplant-eligible Meets extended liver transplant criteria (size, AFP levels) TACE-eligible Well-defined nodules, preserved portal flow, selective access 0 Preserved Recommended for systemic therapy Diffuse, infiltrative, extensive bilobar liver involvement Advanced stage (C) Portal invasions, extrahepatic spread 1–2 Preserved Terminal stage (D) Any tumor burden 3–4 End-stage liver function Abbreviations: AFP, α fetoprotein; TACE, transarterial chemoembolization. The most recent BCLC Staging System was published in 2022 and contains several changes from the 2018 iteration. For one, the 2022 version stratifies intermediate stage (B) HCC into three categories: transplant eligible, TACE eligible, or recommended for systemic therapy.[7] This is a change from the 2018 guidelines which recommended chemoembolization for all intermediate stage (B) lesions, drawing criticism of suboptimal recommendations for such a heterogeneous grouping of patients.[3] This stratification is considerably important for interventional radiologists to be aware of as management of stage B HCC now depends on the nature and/or extent of tumor involvement as well as patients' transplant eligibility. Furthermore, TACE and transarterial radioembolization (TARE) are now recommended as second-line treatments when transplant, ablation, or resection fails in Stage 0 or A HCC.[7] Notably, the recommendations for TARE are limited to lesions ≤ 8 cm based on results of the LEGACY study.[8] In general, it is worth noting that liver transplantation has become increasingly more prevalent in the long-term management of HCC compared with prior BCLC iterations. This is because of the high risk of recurrence of HCC of up to 70% within 5 years after ablation or surgical resection.[9] Liver transplantation is theoretically curative for both HCC and underlying liver disease, and demonstrates ∼50 to 70% survival within 5 years; however, a 10 to 20% reported incidence of HCC recurrence still exists in this patient population.[10] [11] TACE and TARE can be used as bridging treatments prior to transplant, and have demonstrated effectiveness in halting tumor progression and reducing waitlist dropout rates for patients with liver cirrhosis and HCC.[12] [13] [14] [15] Given the increasing prevalence of transplantation as a definitive treatment for HCC and the demonstration of TACE and TARE as effective strategies for improving access to transplantation, this approach to downstaging and bridging to transplant has been included in the 2022 iteration of the BCLC guidelines. New modifications to the role of IR interventions in HCC are summarized in [Table 2]. BCLC 2018 iteration BCLC 2022 iteration Tumor ablation BCLC -Abstract Truncated-

BCLC stage C hepatocellular carcinoma: modern therapeutic strategies in the age of immunotherapy

Camrelizumab (a PD-1 inhibitor) plus apatinib (an VEGFR-2 inhibitor) and hepatic artery infusion chemotherapy for hepatocellular carcinoma in Barcelona Clinic Liver Cancer stage C (TRIPLET): a phase II study

Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A for Nonrandomized, Open-label, Phase II Trial

Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib Plus Humanized Programmed Death Receptor-1 in Patients with High-Risk Advanced Hepatocellular Carcinoma: A Real-World Study

452 Preliminary analysis of a real-world study (RWS) of camrelizumab treatment in primary liver cancer (PLC)

Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study

Abstract 2395: Camrelizumab combined with apatinib and hepatic artery infusion chemotherapy (HAIC) as conversion therapy for patients with unresectable hepatocellular carcinoma(HCC): A single-arm exploratory clinical study

Safety and Efficacy of Atezolizumab and Bevacizumab Combination as a First Line Treatment of Advanced Hepatocellular Carcinoma

Biologics, Immunotherapies, and Cytotoxic Chemotherapy for Hepatocellular Carcinoma following Current Recommendations by the BCLC: A Review of Agents

LBA35 Camrelizumab (C) Plus Rivoceranib (R) Vs. Sorafenib (S) As First-Line Therapy for Unresectable Hepatocellular Carcinoma (uhcc): A Randomized, Phase III Trial

Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report

Assessment of safety and efficacy of transarterial chemoembolization combined with camrelizumab and donafenib in patients with hepatocellular carcinoma at BCLC stage C: A study of 20 cases

Safety and Efficacy of Camrelizumab and Apatinib in Combination with IMRT in Unresectable Hepatocellular Carcinoma: A Non-Randomised Phase 2 Study.

A real-world study of camrelizumab in the treatment of hepatocellular carcinoma.

A phase II/III study of camrelizumab plus apatinib as perioperative treatment of resectable hepatocellular carcinoma at intermediate-high risk of recurrence: Primary results of major pathologic response from phase II stage.

Camrelizumab combined with transcatheter arterial chemoembolization and sorafenib or lenvatinib for unresectable hepatocellular carcinoma: A multicenter, retrospective study

Camrelizumab in combination with TACE for the treatment of unresectable hepatocellular carcinoma (HCC): A multicenter, single-arm, prospective real-world study.

Atezolizumab Plus Bevacizumab Combined with Transarterial Embolization Plus Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma with a Diameter >8 Cm: A Retrospective Study

Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.

PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis

Systemic Drugs for Hepatocellular Carcinoma: What Do Recent Clinical Trials Reveal About Sequencing and the Emerging Complexities of Clinical Decisions?